March 04, 2026

GIMEMA ALL2820: Chemotherapy-Free Regimen Studied in Front-Line Setting

As front-line therapy, a chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed standard treatment ...

The ASCO Post

March 04, 2026

Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes

A new analysis spanning more than 3 decades of Eastern Cooperative Oncology Group and American College of Radiology Imaging Network (ECOG-ACRIN) clinical trial data demonstrates that Black patients wi...

The ASCO Post

March 04, 2026

CD123-Targeting ADC Shows Activity in AML and BPDCN

Researchers presented new data from two ongoing studies of pivekimab sunirine, an antibody-drug conjugate (ADC) targeting CD123, in treating two aggressive blood cancers.

The ASCO Post

February 27, 2026

2024–2025 Drug Updates in Solid Tumors

Explore the latest in solid tumor therapies that prioritize patient quality of life, presented by Dr. Kevin Y. Chen at JADPRO Live 2025.

JADPRO

February 25, 2026

Insights on Sarcomas, Gastroesophageal Cancers, Peritoneal Tumors Anchor Roswell Park Presentations at SSO 2026

A Roswell Park study is shedding light on the little-understood dynamics of the tumor microenvironment (TME) in two types of rare and aggressive sarcomas — dedifferentiated liposarcomas (DDLPS) and leiomyosarcomas (LMS). 

Roswell Park Comprehensive Cancer Center

February 20, 2026

FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma

As reported in the Journal of Clinical Oncology, Maurer et al have developed FLIPI24, a modern prognostic model for newly diagnosed follicular lymphoma.

The ASCO Post

February 15, 2026

Dana-Farber Research News 02.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from January 16 - 31.

Dana-Farber

February 11, 2026

Rethinking the Biology of Chronic Myeloid Leukemia

New research from UC Irvine challenges a long-standing assumption in chronic myeloid leukemia

UCI Health

February 11, 2026

Refining Conditioning Intensity for Older Adults Undergoing Transplant

New data presented at ASH 2025 highlight how age, physiologic reserve and toxicity risk should guide conditioning intensity in older patients undergoing transplant.

UCI Health

February 11, 2026

New data, recurring questions

Where do noncovalent BTK inhibitors fit in chronic lymphocytic leukemia (CLL) care?

UCI Health